- Report
- February 2026
- 371 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 278 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 176 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 380 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 282 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 285 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 104 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 377 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 382 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 198 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 275 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 132 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 196 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 193 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 224 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 126 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 183 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 193 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 277 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- October 2025
- 250 Pages
Global
From €3930EUR$4,490USD£3,416GBP

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs.
Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more